Comparison of Clinical Outcomes of Hydrophilic and Lipophilic Statins in Patients with Acute Myocardial Infarction.
10.3904/kjim.2011.26.3.294
- Author:
Min Chul KIM
1
;
Youngkeun AHN
;
Su Young JANG
;
Kyung Hoon CHO
;
Seung Hwan HWANG
;
Min Goo LEE
;
Jum Suk KO
;
Keun Ho PARK
;
Doo Sun SIM
;
Nam Sik YOON
;
Hyun Ju YOON
;
Kye Hun KIM
;
Young Joon HONG
;
Hyung Wook PARK
;
Ju Han KIM
;
Myung Ho JEONG
;
Jeong Gwan CHO
;
Jong Chun PARK
;
Jung Chaee KANG
Author Information
1. The Heart Center of Chonnam National University Hospital, Gwangju, Korea. cecilyk@hanmail.net
- Publication Type:Original Article ; Comparative Study ; Research Support, Non-U.S. Gov't
- Keywords:
Hydroxymethylglutaryl-CoA reductase inhibitors;
Myocardial infarction
- MeSH:
Aged;
Biological Markers/blood;
Cardiovascular Diseases/etiology/prevention & control;
Chi-Square Distribution;
Female;
Hospital Mortality;
Humans;
Hydrophobic and Hydrophilic Interactions;
Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/chemistry/*therapeutic use;
Korea;
Lipids/blood;
Male;
Middle Aged;
Myocardial Infarction/blood/complications/diagnosis/mortality/*therapy;
Proportional Hazards Models;
Recurrence;
Retrospective Studies;
Risk Assessment;
Risk Factors;
Time Factors;
Treatment Outcome
- From:The Korean Journal of Internal Medicine
2011;26(3):294-303
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: A controversy exists about which statin is preferable for patients with acute myocardial infarction (AMI), and clinical impacts of different statins according to lipophilicity have not been established. METHODS: The 1,124 patients with AMI included in the present study were divided into hydrophilic- and lipophilic-statin groups. In-hospital complications (defined as death, cardiogenic shock, ventricular arrhythmia, infection, bleeding, and renal insufficiency, and other fatal arrhythmias), major adverse cardiac events (MACE), all-cause death, re-myocardial infarction, re-percutaneous coronary intervention (re-PCI), and surgical revascularization were analyzed during a 1-year clinical follow-up. RESULTS: Baseline characteristics were similar between the two groups, and in-hospital complication rates showed no between-group differences (11.7% vs. 12.8%, p = 0.688). Although MACE at the 1- and 6-month clinical follow-ups occurred more in hydrophilic statin group I (1 month: 10.0% vs. 4.4%, p = 0.001; 6 month: 19.9% vs. 14.2%, p = 0.022), no significant difference in MACE was observed at the 1-year follow-up (21.5% vs. 17.9%, p = 0.172). Both statin groups showed similar efficacy for reducing serum lipid concentrations. A Cox-regression analysis showed that the use of a hydrophilic statin did not predict 1-year MACE, all-cause death, AMI, or re-PCI. CONCLUSIONS: Although short-term cardiovascular outcomes were better in the lipophilic-statin group, 1-year outcomes were similar in patients with AMI who were administered hydrophilic and lipophilic statins. In other words, the type of statin did not influence 1-year outcomes in patients with AMI.
